Fosdevirine
Appearance
![]() | |
Clinical data | |
---|---|
Other names | GSK2248761; GSK2248761A; IDX-12899; IDX-899 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C20H17ClN3O3P |
Molar mass | 413.80 g·mol−1 |
3D model (JSmol) | |
| |
|
Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS.[1][2]
It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued[3][4] due to unexpected side effects.[5]
References
- ^ . PMID 26804933.
{{cite journal}}
: Cite journal requires|journal=
(help); Missing or empty|title=
(help) - ^ "Fosdevirine". aidsinfo.nih.gov.
- ^ "Fosdevirine". Adis Insight.
Highest Development Phases: Discontinued, HIV-1 infections
- ^ "Fosdevirine". MedKoo Biosciences.
GSK2248761 is no longer in clinical development.
- ^ . doi:0.3851/IMP2689.
{{cite journal}}
: Check|doi=
value (help); Cite journal requires|journal=
(help); Missing or empty|title=
(help)